Clinical Advances in Innovations in Dyslipidemia and ASCVD | סדרת הרצאות

"Clinical Advances in Innovations in Dyslipidemia and ASCVD" – a Novartis-sponsored Medscape independent medical education (IME) program.
These activities can be accessed on the Medscape online platform.

You can also click on the titles provided below to access each individual education activity.

1. LDL-C and International Guidelines: An Evidence-Based and Practical Approach
Lale Tokgözoğlu (Turkey) and Vera Bittner (USA) discuss similarities and differences in Lipid Guidelines (2018 American College of Cardiology / American Heart Association and 2019 European Society of Cardiology / European Atherosclerosis Society [ESC/EAS]), how to define high risk in dyslipidemia, getting high-risk patients to goal, why high triglycerides matter, and novel lipid lowering therapies.
Released January 05, 2021 and valid for credit until January 05, 2022

2. Recognizing the Advantages and Limitations of Statins in Primary Care
Ulf Landmesser (Germany), Kamlesh Khunti (UK), and Christos Lionis (Greece) discuss CV risk assessment, CV disease burden, guideline-recommended lipid-lowering strategies (statins), and non-statin lipid-lowering therapies, such as inclisiran, and the importance of adherence to treatment.
Released December 10, 2020 and valid for credit until December 10, 2021

3. Nonstatin Therapies and LDL-C Lowering: A Critical Analysis of the Data and Real-World Experiences
Christie M. Ballantyne (USA), M. John Chapman (France), and Frederick J. Raal (South Africa) discuss non-statin (ezetimibe, proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors, bempedoic acid, and inclisiran) therapy, and a combination of statin and non-statin therapies in the prevention and management of ASCVD with a focus on the importance of patient education.
Released Nov 02, 2020 and valid for credit until November 02, 2021

4. Stimulating Health Behavior Change in Primary Care to Improve Dyslipidemia Management
Sarah Jarvis (UK) and Carlos Brotons (Spain) discuss statin intolerance, use of non-statin therapies to attain LDL-C goals, and strategies for effective communication between clinicians and patients to improve adherence to lipid-lowering strategies.
Released Oct 16, 2020 and valid for credit until Oct 16, 2021

5. What Has Changed in Dyslipidemia Management? Setting New Standards of Care
Alberico L. Catapano (Italy), M. John Chapman (France), and Børge Nordestgaard (Denmark) discuss association of high-density lipoproteins, LDL-C, and Lp(a) with ASCVD, current treatment guidelines and recent updates on bempedoic acid and inclisiran.
Released Oct 15, 2020 and valid for credit until Oct 15, 2021

6. Innovative Strategies to Reduce LDL: The Promise of RNA-Based Technologies
Alberico L. Catapano (Italy), Kausik K. Ray (UK), and Frederick J. Raal (South Africa) discuss novel siRNA strategies to block the production of PCSK9 and the clinical trial evidence using this approach to reduce LDL-C in patients at high risk of CV events.
Released Oct 08, 2020 and valid for credit until Oct 08, 2021

7. siRNA: From Bench to Bedside in Future Dyslipidemia Management
Kausik K. Ray (UK) discusses key changes in the 2019 ESC/EAS Guidelines versus those of 2016, the different modalities that block PCSK9, key efficacy data for siRNA treatment in reducing LDL-C, and the difference between monoclonal antibodies and siRNA.
Released Oct 05, 2020 and valid for credit until Oct 05, 2021

8. I Cannot Get my Patient’s LDL-C to Target: What Do the Experts Say?
Henry N. Ginsberg (USA), Ulf Landmesser (Germany), and Raul D. Santos (Brazil) discuss the 2019 ESC/EAS Guidelines for LDL-C management, non-adherence to LDL-C treatment and strategies to overcome challenges. The faculty also advocate for a broader view of atherogenic lipoproteins in subsequent iterations of guidelines. They highlight that elevated Lp(a) is a causal risk factor or enhancer for ASCVD, and mention the ongoing Lp(a) HORIZON trial.
Released Sep 14, 2020 and valid for credit until Sep 14, 2021

9. Risk Assessment in Dyslipidemia for Specialists: An Expert Walkthrough
Lale Tokgözoğlu (Turkey) discusses the Systematic COronary Risk Evaluation (SCORE) system for CV disease risk assessment as recommended by the most recent ESC/EAS Guidelines.
Released Aug 10, 2020 and valid for credit until Aug 10, 2021

10. The Patient Journey With Dyslipidemia: A Patient's Perspective
Christie M. Ballantyne (USA) discusses challenges faced by patients during dyslipidemia treatment and the importance of an individualized treatment approach to address patient needs and improve CV outcomes.
Released July 20, 2020 and valid for credit until July 20, 2021

11. ASCVD and LDL-C: A State of the Art Review on the Latest Science
Jan Borén (Sweden) discusses the latest science on how modulation of LDL-C affects atherosclerotic plaque development and regression.
Released June 29, 2020 and valid for credit until June 29, 2021

12. Familial Hypercholesterolemia: What Every Primary Care Physician Needs to Know
Anne Tybjærg-Hansen (Denmark) discusses the prevalence of familial hypercholesterolemia (FH) and strategies to diagnose FH and initiate lipid-lowering therapy to reduce CV risk. She outlines the causal association of elevated Lp(a) with atherosclerotic stenosis, myocardial infarction and aortic valve stenosis, the high risk for CV disease due to combined high LDL-C and elevated Lp(a), and the importance of measuring Lp(a) at least once in person’s lifetime as per the ESC/EAS Guidelines.
Released June 25, 2020 and valid for credit until June 25, 2021

13. Dyslipidemia Guidelines: Key Takeaways for the Primary Care Physician
François Mach (Switzerland) and Carlos Brotons (Spain) discuss the primary care perspective in the current 2019 ESC/EAS Guidelines to assess risk of CV events, strategies to lower LDL-C in patients with dyslipidemia, and the importance of lifestyle modifications.
Released June 25, 2020 and valid for credit until June 25, 2021